Synthace
Synthace is a software company that powers life science the way it should be done. The company provides a life sciences R&D cloud to scientists who want to innovate faster. The Synthace platform seamlessly automates experimentation and insight sharing so that scientists can focus on asking the most impactful questions and unlocking the true potential of biology.
Sector
Industrial Biotech
Strategies
Crossover & Industrial Biotech
Status
Live
Website
www.synthace.com
Joško Bobanović
Partner, Sofinnova Partners - Industrial Biotech Strategy
Jacques Theurillat
Partner, Sofinnova Partners - Crossover Strategy
Related News
Synthace Raises $35M to Expand Access to Its Revolutionary R&D Technology for Life Changing Research
Synthace and Tecan Announce Collaboration to Accelerate Purification Optimization in Process Development through Augmented Lab Automation
Computer Aided Biology Pioneer Synthace Secures $25.6 Million in Series B Funding
Synthace Launches Ground-Breaking New Whitepaper: Computer-Aided Biology: Delivering Biotechnology in the 21st Century
Synthace Appoints Bob Wiederhold as Chairman of its Board of Directors
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.